다우존스 지수

같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.

등록

홈
인베스팅
주식
미국
AMEX
Can Fite BioPharma Ltd (CANF)
Can Fite BioPharma Ltd (CANF) 뉴스

CANF

Can Fite BioPharma (CANF)

Can Fite BioPharma Ltd

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:AMEX:CANF

1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/05/13	20:03	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	AMEX:CANF	Can Fite BioPharma Ltd
2024/05/13	20:00	Business Wire	Can-Fite: 75 Oncologists and Coordinators from Europe US and Israel Participated in a Conference Aimed at Accelerating Patient Enrolment for the Pivotal Phase 3 Advanced Liver Cancer Study	AMEX:CANF	Can Fite BioPharma Ltd
2024/05/09	20:03	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	AMEX:CANF	Can Fite BioPharma Ltd
2024/05/09	20:00	Business Wire	Can-Fite: FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study	AMEX:CANF	Can Fite BioPharma Ltd
2024/05/06	20:11	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	AMEX:CANF	Can Fite BioPharma Ltd
2024/05/06	20:00	Business Wire	Can-Fite Received Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602	AMEX:CANF	Can Fite BioPharma Ltd
2024/04/25	20:00	Business Wire	Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal	AMEX:CANF	Can Fite BioPharma Ltd
2024/04/15	20:00	Business Wire	Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH	AMEX:CANF	Can Fite BioPharma Ltd
2024/04/03	20:00	Business Wire	Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients	AMEX:CANF	Can Fite BioPharma Ltd
2024/03/28	20:00	Business Wire	Can-Fite Reports 2023 Financial Results and Clinical Update	AMEX:CANF	Can Fite BioPharma Ltd
2024/03/11	20:27	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	AMEX:CANF	Can Fite BioPharma Ltd
2024/03/11	20:00	Business Wire	Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference	AMEX:CANF	Can Fite BioPharma Ltd
2024/02/28	21:06	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	AMEX:CANF	Can Fite BioPharma Ltd
2024/02/28	21:00	Business Wire	Can-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in Canada	AMEX:CANF	Can Fite BioPharma Ltd
2024/02/15	05:32	Edgar (US Regulatory)	Form SC 13G - Statement of acquisition of beneficial ownership by individuals	AMEX:CANF	Can Fite BioPharma Ltd
2024/01/30	21:24	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	AMEX:CANF	Can Fite BioPharma Ltd
2024/01/30	21:00	Business Wire	Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication	AMEX:CANF	Can Fite BioPharma Ltd
2024/01/29	21:05	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	AMEX:CANF	Can Fite BioPharma Ltd
2024/01/29	21:00	Business Wire	Can-Fite: Top Scientific Journal Published Positive Data from the COMFORT-1 Phase III Psoriasis Study	AMEX:CANF	Can Fite BioPharma Ltd
2024/01/08	14:15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	AMEX:CANF	Can Fite BioPharma Ltd
2023/12/29	06:16	Edgar (US Regulatory)	Form F-3/A - Registration statement by foreign private issuers: [Amend]	AMEX:CANF	Can Fite BioPharma Ltd
2023/12/20	21:09	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	AMEX:CANF	Can Fite BioPharma Ltd
2023/12/20	21:00	Business Wire	The Anti-Obesity Effect of Can-Fite’s Namodenoson: Molecular Mechanism of Action in Pre-clinical and Human Studies	AMEX:CANF	Can Fite BioPharma Ltd
2023/12/18	21:07	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	AMEX:CANF	Can Fite BioPharma Ltd
2023/12/18	21:00	Business Wire	Can-Fite Received FDA Positive Response to Psoriasis Pediatric Plan	AMEX:CANF	Can Fite BioPharma Ltd
2023/12/13	06:15	Edgar (US Regulatory)	Form F-3 - Registration statement by foreign private issuers	AMEX:CANF	Can Fite BioPharma Ltd
2023/12/04	21:05	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	AMEX:CANF	Can Fite BioPharma Ltd
2023/12/04	21:00	Business Wire	Can-Fite’s Namodenoson for the Treatment of Pancreatic Cancer Patients: Progress in Clinical Development	AMEX:CANF	Can Fite BioPharma Ltd
2023/11/30	21:05	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	AMEX:CANF	Can Fite BioPharma Ltd
2023/11/30	21:00	Business Wire	Can-Fite Reports Third Quarter 2023 Financial Results and Clinical Update	AMEX:CANF	Can Fite BioPharma Ltd

검색 관련기사 보기:AMEX:CANF

1 2 3 4 5 6 7 8 9 10 다음 >>

CLPM24 - Junho 2024

Eagle Point Credit

Intesa Sanpaolo

Grove Token [OLD]

Vontobel Financial Produ...

Good Works Acquisition

iCandy Interactive

Invesco Peak Retirement ...

Wt Indus Met Ld

Atticus Resources

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관